| |
Puerto Rico offers top-notch talent, smart tax incentives & a robust supply chain, making it a bioscience powerhouse. With the highest concentration of pharma & medical device talent in the U.S., & extensive tax benefits, it’s the top destination for innovation. Visit our booth at BIO to learn more. 
|
|
Today’s Big NewsJun 3, 2024 |
| By Angus Liu After Akeso and Summit's ivonescimab beat Keytruda in a head-to-head trial in non-small cell lung cancer, analysts are trying to sort out the financial ramifications while biopharma insiders are eager to see the exact data. But what does Merck think? |
|
|
|
By Helen Floersh Women have long shouldered the burden of birth control. Now, men may soon have an option that is not only hormone-free, but also allows space between doses. |
By Conor Hale The deal includes Edwards’ Critical Care group and its 4,500 employees, which were previously being set up for a spinoff into an independent company. |
By Gabrielle Masson While 2022 offered quite a few R&D leadership shake-ups, 2023 proved much calmer, with one whopping standout—a $20 million payout for Johnson & Johnson’s new head of pharma R&D. |
|
Wednesday, June 12, 2024 | 11am ET / 8am PT If you are a company developing gene therapies, don’t miss this opportunity to learn about containment and aseptic filling solutions – how to prepare for fill finish early and ensure products are ready to ship immediately upon approval, providing life-saving drugs to patients as quickly as possible. Register now. 
|
|
By Ben Adams,Andrea Park,Nick Paul Taylor AbbVie has toppled Sanofi and Regeneron as the biggest drug ad spender across the pharmaceutical industry in 2023 with a major victory for its next-gen immunology blockbuster Skyrizi. |
By Annalee Armstrong Pharmas have a record $1 trillion to deploy on new innovative deals. All they need is for the Federal Reserve to lower rates, according to a new report from Ernst & Young. |
By Kevin Dunleavy The decision of a Delaware judge on Friday to allow more than 75,000 Zantac lawsuits to go forward to jury trials has left four major drugmakers—GSK, Pfizer, Sanofi and Boehringer Ingelheim—vulnerable to costly awards, settlements and litigation fees as they try to resolve claims that the heartburn drug can cause cancer. |
By Conor Hale A clinical study found that an at-home test based on the DNA found in spit samples could detect cases of prostate cancer that would otherwise slip past a standard blood draw. |
By Angus Liu After Enhertu pioneered the HER2-low category in breast cancer treatment, AstraZeneca and Daiichi Sankyo are now hopeful that the antibody-drug conjugate can reach tumors with an even lower expression of the protein biomarker. |
By Gabrielle Masson As Keytruda’s 2028 patent cliff looms, Merck & Co.’s renewed R&D oncology strategy focuses on three strategies. One of those prongs is improving immune responses, a pillar that stars Moderna-shared cancer vaccine mRNA-4157. |
By Ben Adams AbbVie’s Humira sales slipped last year as the Big Pharma dealt with the first real generic erosion of its immunology megablockbuster, but its backup meds will be more than enough to not just shore up its revenue—but also boost its top line. |
By Andrea Park As a decision date on its proposed asset sale to Merz Therapeutics looms, Acorda Therapeutics still hasn’t lost its fighting spirit. |
By Joseph Keenan South Korean CDMO Lotte Biologics and Merck KGaA signed a partnership deal focused on expanding biopharmaceutical production and process development. |
Fierce podcasts Don’t miss an episode |
| In this week's episode of "The Top Line," two journalists from the Fierce Biotech team share key insights from their four-part series on the challenges and breakthroughs in cell therapy. |
|
|---|
|
|
|
Wednesday, June 19, 2024 |10am ET / 7am PT Join us for a one-hour discussion on oral cyclic peptide drug development. Learn about key breakthroughs that demonstrate results. Register now. 
|
|
Whitepaper New molecular formats are gaining momentum in today’s market. Characterizing these products and developing robust manufacturing processes can help to usher them to market and provide new treatment options for diseases which are currently challenging to treat. Read this white paper to learn more. Presented by: Lonza |
eBook To make every rare disease trial count, we design patient-centric, relevant strategies for sponsors and caregivers to produce impactful results every time. Sponsored by: Emmes Company |
Whitepaper This paper outlines the challenges, pitfalls, & solutions associated with adding rare disease therapies to a biopharma company’s portfolio. Sponsored by: AIM, the strategic leader in life science supply chains |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
